www.ijarp.com ISSN 2456-9992 Page: 01-27

International Journal Advanced Research Publications

Review Article

Volume: 02
Issue: 04

# RABEPRAZOLE IN THE TREATMENT OF ACID-RELATED DISEASES

***Mr. Vijay Kumar, Mr. Devashish Jenna (Assistant Professor)**

India.

**Article Received: 03 March 2026, Article Revised: 21 March 2026, Published on: 11 April 2026**

***Corresponding Author: Mr. Vijay Kumar**

India.

DOI: https://doi-doi.org/101555/ijarp.8015

## ABSTRACT

Rabeprazole is a proton pump inhibitor (PPI). Pharmacodynamic evidence indicates that rabeprazole provides effective acid suppression from the initial dose and sustains this effect during subsequent days of treatment. Furthermore, rabeprazole possesses the highest pKa value (~5.0), which is the pH at which the drug becomes 50% protonated, allowing it to be activated more rapidly at relatively higher pH levels compared to other PPIs. Due to its distinctive metabolic pathway, primarily involving non-enzymatic degradation, rabeprazole is less affected by genetic variations of CYP2C19, leading to minimal impact on its pharmacokinetic and pharmacodynamic profiles.

Regarding clinical effectiveness, rabeprazole 20 mg once daily or 10 mg twice daily demonstrates healing rates at 8 weeks comparable to omeprazole 20 mg once daily in patients with erosive esophagitis. In patients with non-erosive reflux disease (NERD), doses of 10 mg and 20 mg show similar efficacy and are both superior to placebo at 2 and 4 weeks. For the prevention of symptom recurrence, an on-demand regimen with rabeprazole 10 mg daily appears to be beneficial due to its rapid onset of action, with studies in NERD patients confirming its superiority over placebo.

However, long-term continuous therapy, extending up to 5 years, appears to yield better outcomes than on-demand treatment, particularly in individuals with esophagitis. It remains controversial whether reduced doses (10 mg) are truly as effective as the standard dose (20 mg) in these patients. Rabeprazole has also been successfully utilized in managing atypical manifestations of GERD, including dysphagia, GERD-associated asthma, and non-cardiac chest pain, as well as in the management of Barrett's esophagus.

Lastly, rabeprazole demonstrates Helicobacter pylori eradication rates comparable to omeprazole and lansoprazole when administered alongside antibiotics such as amoxicillin and clarithromycin. Additionally, lower doses of rabeprazole (10 mg twice daily) may also be effective in eliminating the infection.

## INTRODUCTION

Rabeprazole is a proton pump inhibitor (PPI) that exerts its action by irreversibly binding to and deactivating the gastric parietal cell proton pump ($H^+/K^+$-ATPase). This mechanism effectively suppresses gastric acid secretion and elevates gastric pH. PPIs are commonly prescribed for the treatment of acid-related conditions such as gastroesophageal reflux disease (GERD) and peptic ulcer disease, and are also used in combination regimens for the eradication of Helicobacter pylori when required.

Rabeprazole has been previously evaluated (Carswell and Goa, 2001). The purpose of the present review is to provide an updated overview of its pharmacological characteristics and clinical applications, particularly emphasizing its role in GERD maintenance therapy, its utility in Barrett's esophagus, and its pharmacoeconomic profile.

### Pharmacology

#### Pharmacodynamics

The most effective approach to increasing gastric pH, and thereby achieving therapeutic benefit in GERD, is the inhibition of proton pump enzymes within parietal cells. All PPIs, which are substituted benzimidazole derivatives, share a common antisecretory mechanism. They accumulate in the secretory canaliculi of parietal cells due to the acidic environment, where they undergo protonation and are converted into an active sulfenamide form (the rate-limiting step). In this activated state, they form covalent disulfide bonds with exposed cysteine residues of the $H^+/K^+$-ATPase enzyme, leading to inhibition of acid secretion.

Although all PPIs act via a similar mechanism, they differ in their acid stability. Structural modifications in rabeprazole confer the highest pKa (~5.0), enabling faster activation at relatively higher pH levels compared to other PPIs. For instance, at pH 1.2 (postprandial canalicular pH), rabeprazole achieves 50% activation in approximately 1.3 minutes, whereas lansoprazole, omeprazole, and pantoprazole require 2.0, 2.8, and 4.6 minutes, respectively. At pH 5.1 (fasting state), rabeprazole again demonstrates the shortest activation half-life.

Experimental models have further confirmed its rapid onset of action. In isolated vesicle studies, rabeprazole produced near-maximal inhibition of the proton pump within 5 minutes,

compared to approximately 30 minutes for lansoprazole and omeprazole, while pantoprazole achieved only partial inhibition within the same timeframe.

Consequently, rabeprazole sodium produces dose-dependent and sustained suppression of both basal and stimulated gastric acid secretion. The antisecretory effect of PPIs is closely associated with their clinical efficacy in acid-related disorders. For example, duodenal ulcer healing correlates with maintaining intragastric pH above 3 for 18–20 hours, whereas healing of erosive GERD requires near-continuous pH levels above 4.

Clinical investigations have demonstrated that rabeprazole provides effective acid suppression from the first dose and maintains this effect over subsequent days, resulting in higher median 24-hour intragastric pH values and longer durations with pH above 3 and 4 compared to omeprazole. Its higher pKa is believed to contribute to its superior early antisecretory effect within the first 24 hours of therapy.

Comparative studies have shown that rabeprazole achieves higher median intragastric pH levels and longer durations of acid control than several other PPIs. While some agents may exhibit stronger acid suppression in the early hours after dosing, rabeprazole demonstrates comparable or superior efficacy over a full 24-hour period. Even at reduced doses, rabeprazole has been shown to provide more effective acid suppression than standard doses of certain other PPIs in specific patient populations.

Additionally, rabeprazole has demonstrated a faster onset of acid inhibition compared to omeprazole, with significantly higher median gastric pH values and prolonged durations of pH above 4 during treatment.

Another clinically relevant phenomenon is nocturnal acid breakthrough (NAB), defined as a decrease in intragastric pH below 4 for at least one hour during nighttime. Rabeprazole has been shown to significantly reduce the duration of NAB when administered either in the morning or evening. It also enhances nocturnal alkaline amplitude, indicating improved nighttime acid control compared to first-generation PPIs.

The pharmacodynamic response of PPIs can be influenced by genetic variations in the CYP2C19 enzyme, which plays a major role in drug metabolism. However, rabeprazole undergoes significant non-enzymatic metabolism and is therefore less affected by CYP2C19 polymorphisms. As a result, its acid-suppressive effect is more consistent and predictable across different patient populations compared to other PPIs.

Another important factor is the regional variation of gastric pH, particularly the presence of the “acid pocket” near the gastroesophageal junction, which contributes to postprandial reflux

symptoms. Rabeprazole has been shown to reduce the size, intensity, and frequency of this acid pocket, thereby potentially decreasing reflux-related symptoms.

Despite its strong antisecretory activity, studies suggest that neither reduced nor standard doses of PPIs consistently achieve the ideal intragastric pH target required for optimal mucosal healing. Nevertheless, rabeprazole maintains a longer duration of pH control compared to equivalent doses of other PPIs.

Beyond acid suppression, rabeprazole exhibits additional protective effects on the gastric mucosa. It has been shown to significantly increase gastric mucin and mucus production, as well as enhance gastric juice viscosity. Furthermore, when co-administered with nonsteroidal anti-inflammatory drugs (NSAIDs) such as naproxen, rabeprazole prevents the reduction in mucosal protective factors. This suggests a direct stimulatory effect on gastric mucous cells, contributing to its protective role in the upper gastrointestinal tract.

**Pharmacokinetics**

Rabeprazole is formulated as an enteric-coated preparation due to the acid-labile nature of proton pump inhibitors. Following oral administration, it is rapidly absorbed, with peak plasma concentration (Cmax) achieved approximately 2.8 to 5.1 hours after dosing.

The pharmacokinetic profile of rabeprazole is linear within the dose range of 10–80 mg, with an overall bioavailability of about 52% for a 20 mg dose. Although Cmax and the area under the plasma concentration–time curve (AUC) increase proportionally with dose, the time to reach peak concentration and the elimination half-life remain unaffected by dose variations. This indicates the absence of saturable first-pass metabolism, allowing efficient absorption even at higher doses.

The bioavailability of rabeprazole is not significantly influenced by concomitant administration of food or antacids. However, food intake may delay drug absorption by approximately 1.7 hours and slightly reduce the apparent elimination half-life, likely due to delayed gastric emptying.

Preclinical investigations have shown that rabeprazole has a volume of distribution of approximately 0.34 L/kg, indicating its distribution across multiple tissues, including gastric mucosa, liver, kidney, intestine, bladder, and thyroid. In healthy individuals, the drug exhibits a high degree of plasma protein binding, ranging from 94.8% to 97.5%.

Repeated dosing does not result in significant drug accumulation, as the elimination half-life is relatively short—about 1 hour after a single dose and approximately 1.5 hours following multiple doses. After administration of a 20 mg dose, nearly 90% of the drug is excreted in

the urine as metabolites (including thioether carboxylic acid, glucuronide, and mercapturic derivatives), while the remaining 10% is eliminated via feces.

Rabeprazole demonstrates a distinctive metabolic pathway compared to other PPIs. While agents such as omeprazole, lansoprazole, esomeprazole, and pantoprazole are primarily metabolized in the liver via the CYP2C19 enzyme, rabeprazole undergoes predominant non-enzymatic conversion to rabeprazole-thioether. A smaller proportion is metabolized through cytochrome P450 isoenzymes, including CYP2C19 (forming demethylated rabeprazole) and CYP3A4 (forming rabeprazole-sulfone).

Genetic polymorphisms in CYP2C19 significantly influence the pharmacokinetics and pharmacodynamics of most PPIs. Individuals are categorized as rapid, intermediate, or poor metabolizers based on their genotype. In general, plasma drug concentrations and intragastric pH levels are lowest in rapid metabolizers and highest in poor metabolizers, thereby affecting therapeutic outcomes in conditions such as GERD and Helicobacter pylori infection.

However, due to its predominant non-enzymatic metabolism, rabeprazole is less affected by CYP2C19 genetic variability. Studies have shown that its AUC, Cmax, and elimination half-life remain consistent across different metabolizer groups, unlike other PPIs such as omeprazole and lansoprazole, which show increased exposure in poor metabolizers. This results in more predictable pharmacokinetic behavior and reduced interindividual variability in clinical response.

Furthermore, rabeprazole maintains a consistent intragastric pH profile irrespective of genetic differences, whereas other PPIs exhibit genotype-dependent variations. This characteristic enhances its reliability in acid suppression across diverse patient populations.

In many individuals, particularly among Caucasians, rapid metabolism of certain PPIs due to CYP2C19 polymorphism may reduce their acid-suppressive efficacy. However, some PPIs like omeprazole and esomeprazole can inhibit CYP2C19 activity through their metabolites, leading to self-inhibition of metabolism and a non-linear increase in plasma concentrations with repeated dosing.

Another important advantage of rabeprazole is its low potential for drug–drug interactions. Due to minimal reliance on cytochrome P450 metabolism, it does not significantly alter the pharmacokinetics of drugs such as theophylline, diazepam, warfarin, or phenytoin. However, like other PPIs, it may influence the absorption of drugs with pH-dependent solubility, such as digoxin and ketoconazole.

Clinical studies evaluating combination therapy with rabeprazole and antibiotics (e.g., clarithromycin and metronidazole) have demonstrated no significant impact on hepatic metabolic function, confirming the absence of clinically relevant metabolic interactions.

Although pharmacokinetic parameters of rabeprazole are altered in certain populations—such as increased Cmax and AUC in elderly individuals and in patients with mild to moderate hepatic impairment—these changes are not associated with significant clinical adverse effects. Additionally, no substantial alterations are observed in patients with renal impairment. Therefore, dose adjustment is generally not required in these special populations. These findings contrast with H2-receptor antagonists, where dosage modifications are often necessary in patients with impaired renal function, but are consistent with the pharmacokinetic profiles of other PPIs.

**Clinical Efficacy Profile in GERD**

Gastroesophageal reflux disease (GERD) is a widespread condition affecting a significant proportion of the Western population and is increasingly prevalent in Eastern regions. There is ongoing debate regarding whether the various manifestations of chronic reflux of gastric contents into the esophagus represent a continuous disease spectrum or distinct, independent subgroups. This distinction is clinically important, as it influences expectations of therapeutic outcomes and the design of clinical trials.

If GERD is considered a spectrum disorder, it encompasses both mild, non-erosive forms and more severe, long-standing erosive or complicated conditions. In this context, preventing progression from symptomatic non-erosive reflux disease (NERD) to erosive esophagitis would be a meaningful therapeutic goal. Conversely, if GERD is viewed as a group of unrelated conditions, such progression may not be considered relevant. For the purpose of this discussion, GERD is regarded as a spectrum disease, including both non-erosive and erosive forms, as well as atypical and extra-esophageal manifestations.

GERD is characterized by symptoms such as heartburn, regurgitation, and belching, which result from exposure of the esophageal mucosa to gastric acid. These symptoms may occur with or without visible mucosal injury on endoscopy. NERD accounts for the majority of GERD cases. Although acid suppression therapy is a rational approach for symptom relief, it is generally considered less effective in NERD patients compared to those with erosive esophagitis, possibly due to reduced responsiveness to antisecretory agents in the postprandial phase.

**Non-Erosive GERD (NERD)**

Clinical studies have demonstrated that rabeprazole is effective in the management of NERD. In a randomized, double-blind, placebo-controlled trial involving 203 patients with moderately severe symptoms, rabeprazole at doses of 10 mg and 20 mg once daily for 4 weeks produced rapid and significant relief of heartburn. Symptom improvement was evident from the first day of treatment and extended to other GERD-related complaints such as regurgitation, bloating, belching, early satiety, and nausea. Both doses were well tolerated and showed clear superiority over placebo in terms of faster onset of symptom relief and increased duration of heartburn-free intervals.

Additional studies using the GERD Symptom Assessment Scale (GSAS) have confirmed that rabeprazole significantly reduces symptom severity and improves patient-reported outcomes compared to placebo. The extent of symptom relief was consistent with improvements in patients' overall perception of their condition.

Further evidence from multicenter clinical trials indicates that rabeprazole provides rapid symptom control, with a significantly shorter time to achieve the first 24-hour heartburn-free period compared to placebo. By the end of 4 weeks, complete relief of heartburn was achieved in a substantially higher proportion of patients receiving rabeprazole. Associated symptoms such as regurgitation and early satiety were also significantly reduced.

Comparative studies have shown that rabeprazole is as effective as other PPIs, such as esomeprazole, in relieving GERD symptoms. Both drugs demonstrated similar onset of action and overall efficacy, with comparable improvements in symptom severity and patient satisfaction.

**Maintenance Therapy and On-Demand Treatment**

NERD is associated with a high rate of symptom recurrence, necessitating effective maintenance strategies. One commonly adopted approach is on-demand therapy, where medication is taken only when symptoms occur. This strategy requires a drug with a rapid onset of action, making rabeprazole a suitable candidate due to its fast acid-suppressive effect.

Clinical studies have demonstrated that on-demand use of rabeprazole provides effective symptom control in both NERD and mild erosive GERD. Patients treated with rabeprazole maintained good symptom control, high levels of satisfaction, and improved quality of life over extended periods. Additionally, the average daily consumption of medication was relatively low, reflecting efficient symptom management.

Randomized controlled trials have further shown that on-demand rabeprazole significantly reduces treatment discontinuation rates compared to placebo, indicating better symptom control. Antacid use was also notably lower in patients receiving rabeprazole.

Comparisons between continuous and on-demand therapy suggest that continuous treatment may offer slightly symptom relief, although the difference is not always statistically significant. However, on-demand therapy is associated with reduced drug consumption and may be preferable for patients with less severe or intermittent symptoms.

**Erosive Reflux Disease (ERD)**

In patients with erosive gastroesophageal reflux disease, the primary therapeutic outcomes include the rate of endoscopically confirmed healing of esophageal erosions and ulcers, as well as the reduction in frequency and intensity of heartburn and other associated gastrointestinal symptoms. In the studies reviewed, all participants were adults with endoscopically verified esophagitis. Common exclusion criteria included recent use of therapeutic doses of proton pump inhibitors or H2-receptor antagonists, as well as the presence of significant comorbid conditions that could interfere with endoscopic evaluation. Approaches to *Helicobacter pylori* testing and eradication varied among studies.

**Healing of Esophagitis and Symptom Relief**

Earlier evidence indicates that rabeprazole administered at 20 mg once daily or 10 mg twice daily achieves comparable healing rates of approximately 90% after 8 weeks of therapy. Similar trends were observed at 4 weeks, with most patients showing clinical response within this initial period. Rabeprazole and omeprazole demonstrate comparable efficacy in reducing both the frequency and severity of GERD symptoms, as well as in improving overall patient well-being.

A randomized, double-blind study involving 230 patients with confirmed erosive esophagitis compared rabeprazole 20 mg with omeprazole 40 mg over a 4-week period, with an additional 4 weeks for non-responders. Both treatments provided similar rates of symptom relief and mucosal healing. However, during the first three days of therapy, patients receiving rabeprazole experienced fewer severe daytime and nighttime heartburn episodes compared to those receiving omeprazole.

A large community-based, open-label study including over 2500 patients demonstrated that rabeprazole 20 mg once daily produces rapid symptom relief. Significant reductions in heartburn severity, regurgitation, and belching were observed as early as the first day of

treatment. Complete resolution of daytime and nighttime heartburn was achieved in a substantial proportion of patients within the first week. The median time to satisfactory symptom control was approximately 2 days. Additionally, health-related quality of life improved significantly following 8 weeks of therapy. Rabeprazole was generally well tolerated, with headache being the most frequently reported adverse effect, occurring in a small percentage of patients.

Comparative clinical trials evaluating rabeprazole against other PPIs, such as omeprazole and lansoprazole, have shown that rabeprazole provides faster symptom relief, particularly in the early phase of treatment. Patients receiving rabeprazole achieved complete resolution of heartburn sooner than those treated with alternative PPIs. However, endoscopic healing rates after 8 weeks were similar across all treatment groups.

Further randomized studies have confirmed that rabeprazole and omeprazole produce equivalent healing outcomes in patients with reflux esophagitis, with healing rates approaching 98% after 4 to 8 weeks of treatment. Notably, the time to achieve initial symptom relief was shorter with rabeprazole, indicating a more rapid onset of action.

Post-marketing surveillance studies have also supported these findings. In patients treated with rabeprazole 20 mg once daily, significant improvements in GERD symptoms—including heartburn, regurgitation, epigastric discomfort, and dysphagia—were observed from the first day of therapy. Endoscopic evaluation revealed healing rates of approximately 77% at 4 weeks and 90% at 8 weeks.

**Relapse Prevention**

The studies discussed in this section were randomized and double-blind, enrolling patients with a prior diagnosis of erosive GERD that had been endoscopically healed within 90 days before inclusion. At baseline, patients were required to show no evidence of active erosions or ulcerations. The primary outcome measure across these studies was the sustained absence of esophageal lesions at follow-up endoscopic evaluation.

Early investigations compared rabeprazole with placebo, while subsequent studies evaluated different dosing regimens of rabeprazole (10 mg vs 20 mg daily) and compared rabeprazole with omeprazole. After one year of therapy, relapse rates were generally low and comparable—approximately 5%—for rabeprazole (both 10 mg and 20 mg daily) and omeprazole 20 mg daily in one study. However, another study reported a significantly lower relapse rate with rabeprazole 20 mg compared to 10 mg (10% vs 27%).

Secondary outcomes, including the frequency and severity of heartburn, overall well-being, daily activity impairment, and antacid consumption, showed no meaningful differences between treatment groups. Kaplan–Meier analyses demonstrated that patients treated with rabeprazole were significantly more likely to remain free from severe daytime and nighttime heartburn compared to placebo, while no significant difference was observed between rabeprazole and omeprazole.

A meta-analysis of comparative studies suggested that rabeprazole may be more effective than some other proton pump inhibitors in preventing symptom recurrence. The estimated recurrence rate with rabeprazole 20 mg daily was lower than that observed with lansoprazole and omeprazole. However, the authors emphasized that these findings were based on a limited number of studies and should be interpreted cautiously.

Long-term maintenance data further support the effectiveness of rabeprazole. In a study involving patients with healed reflux esophagitis maintained on rabeprazole therapy for up to 48 weeks, relapse occurred in approximately 15% of patients.

Extended-duration trials have also been conducted. In a 5-year randomized study comparing rabeprazole (10 mg or 20 mg daily) with omeprazole 20 mg daily, relapse rates were low and similar across all groups, ranging from approximately 10% to 13%. All treatments were well tolerated, and no significant adverse histological findings were observed on gastric biopsy.

Another 5-year study demonstrated that rabeprazole was significantly more effective than placebo in preventing relapse. Relapse rates were substantially higher in the placebo group compared to both rabeprazole groups, and the higher dose (20 mg) showed superior efficacy compared to the lower dose (10 mg). Both dosing regimens also contributed to improved symptom control and enhanced quality of life, without significant safety concerns.

**Barrett's Esophagus (BE)**

Several studies have explored the role of proton pump inhibitor therapy, including rabeprazole, in patients with Barrett's esophagus, particularly focusing on acid and bile reflux control.

In a study evaluating esophageal acid exposure in patients with Barrett's esophagus receiving rabeprazole twice daily, the majority of patients achieved normalization of intra-esophageal pH. However, a subset of patients continued to exhibit abnormal acid exposure despite therapy, with no clear association with demographic or clinical factors such as age, Barrett's segment length, hiatal hernia size, or *Helicobacter pylori* status.

Another prospective study assessed whether switching patients from other PPIs (such as omeprazole or lansoprazole) to rabeprazole could improve acid suppression. While some improvement was observed, a proportion of patients continued to demonstrate abnormal esophageal acid exposure. Additionally, incomplete control of intragastric acidity and the persistence of nocturnal acid breakthrough were noted across different PPI therapies.

More intensive acid suppression strategies have also been investigated. In a small clinical study, high-dose rabeprazole (40 mg three times daily) effectively eliminated acid reflux as confirmed by 24-hour pH monitoring. This approach was used in conjunction with endoscopic cryoablation therapy for Barrett's mucosa. The results indicated a high rate of mucosal regression and suggested that aggressive acid suppression may enhance the effectiveness of endoscopic treatments.

**Atypical (Extra-Esophageal) Symptoms**

Although atypical or extra-esophageal manifestations of gastroesophageal reflux disease (GERD) are clinically significant, they have been less extensively studied compared to typical symptoms. Direct comparative trials among proton pump inhibitors (PPIs) are limited; for instance, systematic reviews of GERD-related asthma treatment have primarily included placebo-controlled studies rather than head-to-head comparisons.

Research evaluating rabeprazole in atypical GERD presentations has focused on conditions such as dysphagia, non-cardiac chest pain, laryngitis, and GERD-associated respiratory and sleep disturbances. However, most of these studies are open-label and lack control groups, which limits the strength of conclusions.

**Dysphagia**

A clinical study involving 68 outpatients with GERD-associated dysphagia evaluated the efficacy of rabeprazole therapy. Following endoscopic assessment, patients received rabeprazole 20 mg daily for 8 weeks, with an extended 6-month treatment at 10 mg daily for those showing improvement. At the end of the study, dysphagia resolved completely in a substantial proportion of patients, partially improved in others, and remained unchanged in a minority. Notably, improvement in dysphagia was closely associated with relief of heartburn symptoms, suggesting that effective acid suppression contributes to symptom resolution.

**Non-Cardiac Chest Pain (PPI Test)**

Rabeprazole has also been evaluated in the diagnostic and therapeutic approach to GERD-related chest pain using the "PPI test." In a randomized, double-blind, placebo-controlled

crossover study, rabeprazole 20 mg twice daily administered for 7 days demonstrated good diagnostic performance, with high sensitivity and specificity. This supports its utility in identifying reflux-related chest pain in clinical practice.

**Respiratory Symptoms and Asthma**

Rabeprazole therapy has shown beneficial effects in patients with GERD-associated asthma. Treatment with 20 mg daily improved peak expiratory flow (PEF) in a significant proportion of patients. The likelihood of improvement was greater in individuals with more severe reflux symptoms and those not dependent on corticosteroids.

Experimental studies further suggest that rabeprazole may reduce cough reflex hypersensitivity, although this effect appears to be independent of changes in airway pH. This indicates a potential additional mechanism beyond acid suppression in alleviating respiratory symptoms.

**Sleep Disturbances**

GERD is often associated with impaired sleep quality. Short-term treatment with rabeprazole (20 mg twice daily) has been shown to improve subjective measures of sleep quality and reduce perceived reflux symptoms. However, objective assessments using polysomnography and pH monitoring indicate that nocturnal acid exposure and sleep architecture may not be significantly altered.

**Chronic Laryngitis (Laryngopharyngeal Reflux)**

Chronic laryngitis is another recognized extra-esophageal manifestation of GERD. Open-label studies have demonstrated that rabeprazole 20 mg twice daily administered for two months can significantly improve symptoms such as hoarseness and throat discomfort, along with partial resolution of laryngeal findings.

However, controlled trials suggest that lifestyle modifications alone may produce substantial improvement in laryngopharyngeal symptoms, and the addition of rabeprazole does not always provide additional benefit. Treatment outcomes appear to depend largely on patient adherence to lifestyle changes and improvement in typical reflux symptoms.

**Cardiac-like Symptoms (Angina-like Pain)**

In patients with coronary artery disease, rabeprazole therapy has been shown to reduce the frequency of angina-like chest pain and improve exercise tolerance as measured by treadmill

testing. These findings suggest that a proportion of chest pain symptoms in such patients may be attributable to underlying GERD.

**Pharmacoeconomics and Quality of Life**

Gastroesophageal reflux disease (GERD) is a chronic and relapsing disorder, and a substantial proportion of patients require prolonged maintenance therapy. Consequently, the use of proton pump inhibitors (PPIs) has increased significantly, leading to rising healthcare costs. Therefore, the initial therapeutic choice has important long-term economic implications.

Economic models incorporating direct medical costs—such as hospital admissions, diagnostic procedures, and outpatient visits—have been developed to compare treatment strategies. One such model demonstrated that although rabeprazole therapy was associated with a slightly higher per-patient cost compared to ranitidine, it was more effective in preventing symptom recurrence. Moreover, rabeprazole exhibited a more favorable cost-effectiveness ratio, suggesting that it may represent a more efficient treatment option despite higher upfront costs.

The appropriateness of PPI prescribing has also been evaluated in clinical practice. Observational data from hospital settings indicate that a significant proportion of patients receive PPIs without clear or approved indications, and many do not undergo confirmatory endoscopic evaluation. Among available PPIs, rabeprazole—despite being one of the less expensive options—has been relatively underutilized. Substituting higher-cost PPIs with more economical alternatives, including generic formulations and rabeprazole, may lead to substantial cost savings when aligned with appropriate clinical indications.

Decision-analysis models comparing treatment strategies suggest that a “PPI test” followed by a step-down approach may improve symptom control, enhance quality of life, and optimize the use of diagnostic procedures, with only a modest increase in overall costs. Further cost reductions may be achieved by transitioning from higher initial doses to maintenance dosing once symptom control is established.

Comparative cost-effectiveness analyses have shown that rabeprazole and generic omeprazole are among the most economical options for managing GERD. These agents are associated with a greater number of symptom-free days and improved quality-adjusted life years (QALYs). Rabeprazole, in particular, demonstrates a favorable cost-effectiveness profile, maintaining its economic advantage across both continuous and on-demand treatment strategies.

In patients with non-erosive reflux disease, on-demand rabeprazole therapy has been associated with the lowest treatment costs compared to other PPIs, while maintaining similar clinical outcomes. These findings are consistent across various sensitivity analyses, supporting the robustness of the economic advantage.

Cost-minimization studies evaluating acid suppression (measured by intragastric pH holding time above 4) indicate that rabeprazole is among the least expensive options for achieving effective acid control over extended periods.

Large population-based studies have further demonstrated that patients treated with rabeprazole incur lower GERD-related healthcare costs, require fewer dose escalations, and consume fewer tablets per day compared to those receiving other PPIs. Treatment adherence appears comparable across different PPIs, and increased compliance does not necessarily correlate with reduced overall costs.

**Quality of Life Outcomes**

Beyond economic considerations, rabeprazole has demonstrated significant benefits in improving patient quality of life. Clinical trials comparing rabeprazole with histamine H2-receptor antagonists have shown superior outcomes in terms of symptom relief, overall well-being, and reduced impairment in daily activities.

Quality of life assessments using standardized tools, such as the SF-36 Health Survey, have revealed significant improvements across multiple domains following rabeprazole therapy. These include enhancements in social functioning, emotional well-being, and role limitations due to physical and psychological factors. In many cases, treatment restored quality of life scores to levels comparable to those observed in the general population.

Additional studies evaluating patients with both investigated and uninvestigated GERD have demonstrated high rates of symptom resolution with rabeprazole therapy, along with corresponding improvements in psychological well-being. These benefits were observed irrespective of *Helicobacter pylori* infection status, although greater efficacy was noted in patients with erosive disease compared to those with non-erosive reflux.

**Possible New Indications**

Emerging evidence suggests that proton pump inhibitors (PPIs), including rabeprazole, may have potential applications beyond acid-related disorders. One proposed mechanism of tumor resistance to chemotherapy involves alterations in the tumor microenvironment, particularly changes in the pH gradient between the extracellular space and the intracellular cytoplasm.

This altered pH environment can reduce the uptake of weakly basic chemotherapeutic agents, thereby diminishing their therapeutic effectiveness.

Targeting proton transport systems, such as vacuolar $H^+$-ATPases (V-$H^+$-ATPases), represents a potential strategy to overcome multidrug resistance. Rabeprazole has been shown to directly inhibit these proton pumps, leading to modulation of intracellular and extracellular pH. Preclinical studies have demonstrated that pretreatment with PPIs can sensitize tumor cell lines to chemotherapeutic agents such as cisplatin, 5-fluorouracil, and vinblastine. This effect is associated with inhibition of V-$H^+$-ATPase activity, increased extracellular pH, and alkalinization of lysosomal compartments, resulting in enhanced intracellular retention and nuclear targeting of cytotoxic drugs, such as doxorubicin.

In vitro investigations have further indicated that very high concentrations of rabeprazole can enhance drug uptake mediated by the MDR1 transporter, increasing rhodamine 123 accumulation in various cancer cell lines. However, at clinically relevant plasma concentrations, this interaction is likely to be minimal, suggesting limited direct impact in routine therapeutic use.

In addition to its potential role in oncology, rabeprazole and other substituted benzimidazoles have demonstrated in vitro antimalarial activity against different strains of *Plasmodium falciparum*, including those resistant to conventional antimalarial agents such as chloroquine and pyrimethamine. Among these agents, rabeprazole and lansoprazole showed relatively higher efficacy.

Despite these promising findings, the clinical relevance of these effects remains uncertain, and further research is required to determine whether these experimental observations can be translated into therapeutic applications in humans.

## CONCLUSION

Rabeprazole is a well-established proton pump inhibitor with a favorable pharmacological and clinical profile in the management of acid-related disorders. Its rapid onset of action, higher pKa, and partially non-enzymatic metabolism contribute to effective and consistent acid suppression, with minimal influence from genetic polymorphisms such as CYP2C19. These characteristics provide an advantage in achieving early symptom relief and predictable therapeutic outcomes compared to other PPIs.

Clinically, rabeprazole demonstrates comparable efficacy to other PPIs in healing erosive esophagitis and managing non-erosive reflux disease (NERD), while often offering faster symptom control. It is also effective in long-term maintenance therapy, with low relapse rates

and flexible dosing strategies, including continuous and on-demand use. Additionally, rabeprazole has shown potential benefits in managing atypical and extra-esophageal manifestations of GERD, although evidence in these areas remains limited.

From a pharmacoeconomic perspective, rabeprazole provides a favorable balance between cost and effectiveness. It reduces symptom recurrence, improves quality of life, and may lower overall healthcare utilization despite slightly higher direct costs in some settings.

Emerging research also suggests potential novel applications of rabeprazole beyond acid suppression, including roles in overcoming tumor drug resistance and possible antimalarial activity. However, these findings are largely based on preclinical studies and require further clinical validation.

## REFERENCES


1. Adachi K, Hashimoto T, Hamamoto N, et al. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J Gastroenterol Hepatol. 2003;18:1392–8. doi: 10.1046/j.1440-1746.2003.03190.x. [DOI] [PubMed] [Google Scholar]
2. Adachi K, Katsube T, Kawamura A, et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther. 2000;14:1259–66. doi: 10.1046/j.1365-2036.2000.00840.x. [DOI] [PubMed] [Google Scholar]
3. Ando T, Kato H, Sugimoto N, et al. A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences. Dig Dis Sci. 2005;50:1625–31. doi: 10.1007/s10620-005-2907-z. [DOI] [PubMed] [Google Scholar]
4. Archimandritis AJ, Nikolopoulou V, Kouklakis G, et al. Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study. Curr Med Res Opin. 2005;21:603–10. doi: 10.1185/030079905X41444. [DOI] [PubMed] [Google Scholar]
5. Barth J, Perdomo C, Sloan S. Rabeprazole maintains GERD healing in patients with Barrett's esophagus. Am J Gastroenterol. 1999;94:2579. [Google Scholar]
6. Bell NJ, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion. 1992;51(Suppl 1):59–67. doi: 10.1159/000200917. [DOI] [PubMed] [Google Scholar]

7. Besancon M, Simon A, Sachs G, et al. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem. 1997;272:22438–46. doi: 10.1074/jbc.272.36.22438. [DOI] [PubMed] [Google Scholar]
8. Birbara C, Breiter J, Perdomo C, et al. Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group. Eur J Gastroenterol Hepatol. 2000;12:889–97. doi: 10.1097/00042737-200012080-00008. [DOI] [PubMed] [Google Scholar]
9. Bour B, Staub JL, Chousterman M, et al. Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment Pharmacol Ther. 2005;21:805–12. doi: 10.1111/j.1365-2036.2005.02413.x. [DOI] [PubMed] [Google Scholar]
10. Bruley Des Varannes S, Gharib H, Bicheler V, et al. Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects. Aliment Pharmacol Ther. 2004;20:899–907. doi: 10.1111/j.1365-2036.2004.02176.x. [DOI] [PubMed] [Google Scholar]
11. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology. 1990;99:345–51. doi: 10.1016/0016-5085(90)91015-x. [DOI] [PubMed] [Google Scholar]
12. Bytzer P, Blum A, De Herdt D, et al. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2004;20:181–8. doi: 10.1111/j.1365-2036.2004.01999.x. [DOI] [PubMed] [Google Scholar]
13. Caos A, Breiter J, Perdomo C, et al. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. Aliment Pharmacol Ther. 2005;22:193–202. doi: 10.1111/j.1365-2036.2005.02555.x. [DOI] [PubMed] [Google Scholar]
14. Caos A, Moskovitz M, Dayal Y, et al. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Am J Gastroenterol. 2000;95:3081–8. doi: 10.1111/j.1572-0241.2000.03179.x. [DOI] [PubMed] [Google Scholar]

15. Carswell CI, Goa KL. Rabeprazole: an update of its use in acid related disorders. Drugs. 2001;61:2327–56. doi: 10.2165/00003495-200161150-00016. [DOI] [PubMed] [Google Scholar]
16. Catalano F, Terminella C, Branciforte G, et al. Eradication therapy with rabeprazole versus omeprazole in the treatment of active duodenal ulcer. Digestion. 2002;66:154–9. doi: 10.1159/000066756. [DOI] [PubMed] [Google Scholar]
17. Damiano A, Siddique R, Xu X, et al. Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. Dig Dis Sci. 2003;48:657–62. doi: 10.1023/a:1022812103923. [DOI] [PubMed] [Google Scholar]
18. De Milito A, Fais S. Proton pump inhibitors may reduce tumour resistance. Expert Opin Pharmacother. 2005;6:1049–54. doi: 10.1517/14656566.6.7.1049. [DOI] [PubMed] [Google Scholar]
19. Dean BB, Siddique RM, Yamashita BD. Cost-effectiveness of proton pump inhibitors for maintenance therapy of erosive reflux esophagitis. Am J Health Syst Pharm. 2001;58:1338–46. doi: 10.1093/ajhp/58.14.1338. [DOI] [PubMed] [Google Scholar]
20. Dekkers CP, Beker JA, Thjodleifsson B, et al. Double-blind comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther. 1999;13:49–57. doi: 10.1046/j.1365-2036.1999.00438.x. [DOI] [PubMed] [Google Scholar]
21. Di Mario F, Dal Bo N, Aragona G, et al. Rabeprazole in a one-week eradication therapy of Helicobacter pylori: comparison of different dosages. J Gastroenterol Hepatol. 2003;18:783–6. doi: 10.1046/j.1440-1746.2003.03035.x. [DOI] [PubMed] [Google Scholar]
22. Dickman R, Emmons S, Cui H, et al. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Aliment Pharmacol Ther. 2005;22:547–55. doi: 10.1111/j.1365-2036.2005.02620.x. [DOI] [PubMed] [Google Scholar]
23. Dubois D, Hughes DA, Bodger K, et al. Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease. Pharmacoeconomics. 2005;23:1031–41. doi: 10.2165/00019053-200523100-00006. [DOI] [PubMed] [Google Scholar]

24. Farley A, Wruble LD, Humphries TJ. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group. Am J Gastroenterol. 2000;95:1894–9. doi: 10.1111/j.1572-0241.2000.02233.x. [DOI] [PubMed] [Google Scholar]
25. Fass R, Ofman JJ. Gastroesophageal reflux disease: should we adopt a new conceptual framework? Am J Gastroenterol. 2002;97:1901–9. doi: 10.1111/j.1572-0241.2002.05912.x. [DOI] [PubMed] [Google Scholar]
26. Feldman M, Burton ME. Histamine H2-receptor antagonists. N Engl J Med. 1990;323:1672–80. doi: 10.1056/NEJM199012133232405. [DOI] [PubMed] [Google Scholar]
27. Fletcher J, Wirz A, Young J, Vallance R, McColl KE. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology. 2001;121:775–83. doi: 10.1053/gast.2001.27997. [DOI] [PubMed] [Google Scholar]
28. Fock KM, Teo EK, Ang TL, et al. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia. World J Gastroenterol. 2005;11:3091–8. doi: 10.3748/wjg.v11.i20.3091. [DOI] [PMC free article] [PubMed] [Google Scholar]
29. Fuhr U, Jetter A. Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie. 2002;57:595–601. [PubMed] [Google Scholar]
30. Furuta T, Shirai N, Sugimoto M, et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005;20:153–67. doi: 10.2133/dmpk.20.153. [DOI] [PubMed] [Google Scholar]
31. Gambaro C, Bilardi C, Dulbecco P, et al. Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a prelimary study. Dig Liv Dis. 2003;35:763–7. doi: 10.1016/s1590-8658(03)00458-4. [DOI] [PubMed] [Google Scholar]
32. Gardner JD, Gallo-Torres H, Sloan S, et al. The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis. Aliment Pharmacol Ther. 2003;18:891–905. doi: 10.1046/j.1365-2036.2003.01777.x. [DOI] [PubMed] [Google Scholar]
33. Gerson LB, Shetler K, Triadafilopoulos G. Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett's oesophagus. Dig Liv Dis. 2005;37:651–8. doi: 10.1016/j.dld.2005.04.013. [DOI] [PubMed] [Google Scholar]

34. Giannini EG, Bilardi C, Dulbecco P, et al. A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2006;23:281–7. doi: 10.1111/j.1365-2036.2006.02756.x. [DOI] [PubMed] [Google Scholar]
35. Giannini EG, Malfatti F, Botta F, et al. Influence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin and metronidazole on 13C-aminopyrine breath test. Dig Dis Sci. 2005;50:1207–13. doi: 10.1007/s10620-005-2761-z. [DOI] [PubMed] [Google Scholar]
36. Gibson PG, Henry RL, Coughlan JL. Gastro-oesophageal reflux treatment for asthma in adults and children. The Cochrane Database of Systematic Reviews. 2003;Issue 1 doi: 10.1002/14651858.CD001496. Art. No.: CD001496. DOI: 10.1002/14651858.CD001496. [DOI] [PubMed] [Google Scholar]
37. Gisbert JP, Khorrami S, Calvet X, et al. Systematic review: rabeprazole-based therapies in Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003;17:751–64. doi: 10.1046/j.1365-2036.2003.01450.x. [DOI] [PubMed] [Google Scholar]
38. Gisbert JP, Pajares JM. Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Aliment Pharmacol Ther. 2005;21:795–804. doi: 10.1111/j.1365-2036.2005.02418.x. [DOI] [PubMed] [Google Scholar]
39. Hall J, Dodd S, Durkin M, et al. An impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs. Managed Care. 2002;11(Suppl 7):14–8. [PubMed] [Google Scholar]
40. Holtmann G, Bytzer P, Metz M, et al. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002;16:479–85. doi: 10.1046/j.1365-2036.2002.01207.x. [DOI] [PubMed] [Google Scholar]
41. Horn J. Review article: relationship between the metabolism and efficacy of proton pump inhibitors – focus on rabeprazole. Aliment Pharmacol Ther. 2004;20(Suppl 6):11–9. doi: 10.1111/j.1365-2036.2004.02161.x. [DOI] [PubMed] [Google Scholar]
42. Hunt RH, Armstrong D, James C, et al. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol. 2005;100:1949–56. doi: 10.1111/j.1572-0241.2005.41956.x. [DOI] [PubMed] [Google Scholar]

43. Inamori M, Togawa J, Takahashi K, et al. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy? J Gastroenterol Hepatol. 2003;18:1034–8. doi: 10.1046/j.1440-1746.2003.03126.x. [DOI] [PubMed] [Google Scholar]
44. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors – emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13(Suppl 3):27–36. doi: 10.1046/j.1365-2036.1999.00022.x. [DOI] [PubMed] [Google Scholar]
45. Itagaki F, Homma M, Takara K, et al. Effect of rabeprazole on MDR1-mediated transport of Rhodamine 123 in Caco-2 and Hvr100-6 cells. Biol Pharm Bull. 2004;27:1694–6. doi: 10.1248/bpb.27.1694. [DOI] [PubMed] [Google Scholar]
46. Jaworski T, Sarosiek I, Sostarich S, et al. Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance. Dig Dis Sci. 2005;50:357–65. doi: 10.1007/s10620-005-1611-3. [DOI] [PubMed] [Google Scholar]
47. Ji S, Kim HS, Kim JW, et al. Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases. J Gastroenterol Hepatol. 2006:1–7. doi: 10.1111/j.1440-1746.2006.04314.x. [DOI] [PubMed] [Google Scholar]
48. Johnsson F, Moum B, Vilien M, et al. On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole. Scand J Gastroenterol. 2002;37:pag642–7. doi: 10.1080/00365520212499. [DOI] [PubMed] [Google Scholar]
49. Johanson JF, Siddique R, Damiano AM, et al. Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease. Dig Dis Sci. 2002;47:2574–8. doi: 10.1023/a:1020532714664. [DOI] [PubMed] [Google Scholar]
50. Johnston MH, Eastone JA, Horwhat JD, et al. Cryoablation of Barrett's esophagus: a pilot study. Gastrointest Endosc. 2005;62:842–8. doi: 10.1016/j.gie.2005.05.008. [DOI] [PubMed] [Google Scholar]
51. Kahrilas PJ, Miner P, Johanson J, et al. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. Dig Dis Sci. 2005;50:2009–18. doi: 10.1007/s10620-005-3000-3. [DOI] [PubMed] [Google Scholar]
52. Kawabata H, Habu Y, Tomioka H, et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor,

amoxicillin and clarithromycin. Aliment Pharmacol Ther. 2003;17:259–64. doi: 10.1046/j.1365-2036.2003.01406.x. [DOI] [PubMed] [Google Scholar]

53. Kivioja A, Linnosmaa I, Vehvilainen A, et al. Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions. Eur J Pharm Sci. 2004;21:171–8. doi: 10.1016/j.ejps.2003.10.004. [DOI] [PubMed] [Google Scholar]
54. Klopocka M, Sinkiewicz A, Budzynski J, et al. Improvement in clinical course and laryngeal appearance in selected patients with chronic laryngitis after eight weeks of therapy with rabeprazole. Med Sci Monit. 2004;10:PI115–8. [PubMed] [Google Scholar]
55. Kromer W, Kruger U, Huber R, et al. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology. 1998;56:57–70. doi: 10.1159/000028183. [DOI] [PubMed] [Google Scholar]
56. Lew EA, Barbuti RC, Kovacs TO, et al. An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810) Aliment Pharmacol Ther. 1998;12:667–72. doi: 10.1046/j.1365-2036.1998.00356.x. [DOI] [PubMed] [Google Scholar]
57. Luo JY, Niu CY, Wang XQ, et al. Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude. World J Gastroenterol. 2003;9(11):2583–6. doi: 10.3748/wjg.v9.i11.2583. [DOI] [PMC free article] [PubMed] [Google Scholar]
58. Mat Saad AZ, Collins N, Lobo MM, et al. Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract. 2005;59:31–4. doi: 10.1111/j.1742-1241.2004.00298.x. [DOI] [PubMed] [Google Scholar]
59. McColl KEL, Kennerley P. Proton pump inhibitors – differences emerge in hepatic metabolism. Dig Liv Dis. 2002;34:461–7. doi: 10.1016/s1590-8658(02)80102-5. [DOI] [PubMed] [Google Scholar]
60. McGowan B, Bennett K, Tilson L, et al. Cost-effective prescribing of proton pump inhibitors (PPI's) in the GMS Scheme. Ir Med J. 2005;98:78–80. [PubMed] [Google Scholar]
61. Miner P, Jr, Orr W, Filippone J, et al. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol. 2002;97:1332–9. doi: 10.1111/j.1572-0241.2002.05769.x. [DOI] [PubMed] [Google Scholar]

62. Oda K, Iwakiri R, Hara M, et al. Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor. Dig Dis Sci. 2005;50:1921–6. doi: 10.1007/s10620-005-2962-5. [DOI] [PubMed] [Google Scholar]
63. Ofman JJ, Dorn GH, Fennerty MB, et al. The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002;16:261–73. doi: 10.1046/j.1365-2036.2002.01167.x. [DOI] [PubMed] [Google Scholar]
64. Ofman JJ, Yamashita BD, Siddique RM, et al. Cost-effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis. Am J Manag Care. 2000;6:905–16. [PubMed] [Google Scholar]
65. Ohning GV, Walsh JH, Pisegna JR, et al. Rabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjects. Aliment Pharmacol Ther. 2003;17:1109–14. doi: 10.1046/j.1365-2036.2003.01573.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
66. Oribe Y, Fujimura M, Kita T, et al. Attenuating effect of H+K+ATPase inhibitors on airway cough hypersensitivity induced by allergic airway inflammation in guinea-pigs. Clin Exp Allergy. 2005;35:262–7. doi: 10.1111/j.1365-2222.2005.02158.x. [DOI] [PubMed] [Google Scholar]
67. Orr WC, Goodrich S, Robert J. The effect of acid suppression on sleep patterns and sleep-related gastro-oesophageal reflux. Aliment Pharmacol Ther. 2005;21:103–8. doi: 10.1111/j.1365-2036.2005.02310.x. [DOI] [PubMed] [Google Scholar]
68. Pace F, Annese V, Prada A, et al. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomized, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux, followed by a maintenance open-label, low-dose therapy with rabeprazole. Dig Liver Dis. 2005;37:741–50. doi: 10.1016/j.dld.2005.04.026. [DOI] [PubMed] [Google Scholar]
69. Pace F, Bianchi-Porro G. Gastroesophageal reflux disease: a typical spectrum disease (a new conceptual framework is not needed) Am J Gastroenterol. 2004;99:946–9. doi: 10.1111/j.1572-0241.2004.04164.x. [DOI] [PubMed] [Google Scholar]
70. Pace F, Pallotta S, Bianchi Porro G. On demand proton pump therapy in patients with gastro-esophageal reflux disease. Dig Liver Dis. 2002;34:870–7. doi: 10.1016/s1590-8658(02)80259-6. [DOI] [PubMed] [Google Scholar]

71. Pantoflickova D, Dorta G, Ravic M, et al. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther. 2003;17:1507–14. doi: 10.1046/j.1365-2036.2003.01496.x. [DOI] [PubMed] [Google Scholar]
72. Pehlivanov ND, Olyaee M, Sarosiek I, et al. Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. Aliment Pharmacol Ther. 2003;18:883–90. doi: 10.1046/j.1365-2036.2003.01776.x. [DOI] [PubMed] [Google Scholar]
73. Ponce J, Arguello L, Bastida G, et al. On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. Dig Dis Sci. 2004;49:931–6. doi: 10.1023/b:ddas.0000034551.39324.c3. [DOI] [PubMed] [Google Scholar]
74. Remak E, Brown RE, Yuen C, et al. Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK. Curr Med Res Opin. 2005;21:1505–17. doi: 10.1185/030079905X65330. [DOI] [PubMed] [Google Scholar]
75. Riel MA, Kyle DE, Bhattacharjee AK, et al. Efficacy of proton pump inhibitor drugs against Plasmodium falciparum in vitro and their probable pharmacophores. Antimicrob Agents Chemother. 2002;46:2627–32. doi: 10.1128/AAC.46.8.2627-2632.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
76. Robinson M, Fitzgerald S, Hegedus R, et al. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther. 2002;16:445–54. doi: 10.1046/j.1365-2036.2002.01181.x. [DOI] [PubMed] [Google Scholar]
77. Saitoh T, Fukushima Y, Otsuka H, et al. Effects or rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther. 2002;16:1811–7. doi: 10.1046/j.1365-2036.2002.01348.x. [DOI] [PubMed] [Google Scholar]
78. Sakai T, Aoyama N, Kita T, et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res. 2001;18:721–7. doi: 10.1023/a:1011035007591. [DOI] [PubMed] [Google Scholar]

79. Sarela AI, Hick DG, Verbeke CS, et al. Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy. Arch Surg. 2004;139:547–51. doi: 10.1001/archsurg.139.5.547. [DOI] [PubMed] [Google Scholar]
80. Shimatani T, Inoue M, Kuroiwa T, et al. Acid-suppressive effects of rabeprazole, omeprazole and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. Clin Pharmacol Ther. 2006;79:144–52. doi: 10.1016/j.clpt.2005.09.012. [DOI] [PubMed] [Google Scholar]
81. Shirai N, Furuta T, Moriyama Y, et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther. 2001;15:1929–37. doi: 10.1046/j.1365-2036.2001.01108.x. [DOI] [PubMed] [Google Scholar]
82. Skoczylas T, Sarosiek I, Sostarich S, et al. Significant enhancement of gastric mucin content after rabeprazole administration. Its potential clinical significance in acid-related disorders. Dig Dis Sci. 2003;48:322–8. doi: 10.1023/a:1021983611768. [DOI] [PubMed] [Google Scholar]
83. Sloan S. Rabeprazole-based therapy in the management of symptomatic gastroesophageal reflux disease. Am J Gastroenterol. 2003;98(3 Suppl):S49–S55. doi: 10.1016/s0002-9270(03)00015-7. [DOI] [PubMed] [Google Scholar]
84. Steward DL, Wilson KM, Kelly DH, et al. Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial. Otolaryngol Head Neck Surg. 2004;131:342–50. doi: 10.1016/j.otohns.2004.03.037. [DOI] [PubMed] [Google Scholar]
85. Swan SK, Hoyumpa AM, Merritt GJ. Review article: the pharmacokinetics of rabeprazole in health and disease. Aliment Pharmacol Ther. 1999;13(Suppl 3):11–7. doi: 10.1046/j.1365-2036.1999.00020.x. [DOI] [PubMed] [Google Scholar]
86. Swiatkowski M, Budzynski J, Klopocka M, et al. Suppression of gastric acid production may improve the course of angina pectoris and the results of treadmill stress test in patients with coronary artery disease. Med Sci Monit. 2004;10:CR524–9. [PubMed] [Google Scholar]
87. Thjodleifsson B, Cockburn I. Review article: rabeprazole's tolerability profile in clinical trials. Aliment Pharmacol Ther. 1999;13(Suppl 5):17–23. doi: 10.1046/j.1365-2036.1999.00035.x. [DOI] [PubMed] [Google Scholar]

88. Thjodleifsson B, Rindi G, Fiocca R, et al. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. Aliment Pharmacol Ther. 2003;17:343–51. doi: 10.1046/j.1365-2036.2003.01446.x. [DOI] [PubMed] [Google Scholar]
89. Thjodleifsson B. Review of rabeprazole in the treatment of gastro-oesophageal reflux disease. Expert Opin Pharmacother. 2004;5:137–49. doi: 10.1517/14656566.5.1.137. [DOI] [PubMed] [Google Scholar]
90. Thjodleifsson B, Beker JA, Dekkers C. Rabeprazole vs omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double blind multicenter European trial. The European Rabeprazole Study Group. Dig Dis Sci. 2000;45:845–53. doi: 10.1023/a:1005548318996. [DOI] [PubMed] [Google Scholar]
91. Tolman KG, Täubel J, Warrington S, et al. Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteers. Clin Drug Invest. 2006;26:21–8. doi: 10.2165/00044011-200626010-00003. [DOI] [PubMed] [Google Scholar]
92. Tsugeno H, Mizuno M, Fujiki S, et al. A proton-pump inhibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal reflux. Scand J Gastroenterol. 2003;38:456–61. doi: 10.1080/00365520310002490. [DOI] [PubMed] [Google Scholar]
93. Vakil N, Lanza F, Schwartz H, et al. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther. 2004;20:99–107. doi: 10.1111/j.1365-2036.2004.02029.x. [DOI] [PubMed] [Google Scholar]
94. Van Herwaarden MA, Samson M, Smout AJ. Helicobacter pylori eradication increases nocturnal acid breakthrough. Aliment Pharmacol Ther. 2000;14:961–2. doi: 10.1046/j.1365-2036.2000.00769.x. [DOI] [PubMed] [Google Scholar]
95. Vo L, Simonian HP, Doma S, et al. The effect of rabeprazole on regional gastric acidity and the postprandial cardia/gastro-oesophageal junction acid layer in normal subjects: a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2005;21:1321–30. doi: 10.1111/j.1365-2036.2005.02489.x. [DOI] [PubMed] [Google Scholar]
96. Wang H, Chou J, Liao K, et al. One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple

therapy. World J Gastroenterol. 2005;11:1680–4. doi: 10.3748/wjg.v11.i11.1680. [DOI] [PMC free article] [PubMed] [Google Scholar]

97. Wani S, Sampliner RE, Weston AP, et al. Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus. Aliment Pharmacol Ther. 2005;22:627–33. doi: 10.1111/j.1365-2036.2005.02626.x. [DOI] [PubMed] [Google Scholar]
98. Warrington S, Baisley K, Boyce M, et al. Effects of rabeprazole 20 mg, or esomeprazole 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol Ther. 2002;16:1301–7. doi: 10.1046/j.1365-2036.2002.01292.x. [DOI] [PubMed] [Google Scholar]
99. Williams MP, Sercombe J, Hamilton MI, et al. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther. 1998;12:1079–89. doi: 10.1046/j.1365-2036.1998.00418.x. [DOI] [PubMed] [Google Scholar]
100. Wit NJ, Boer WA, Geldof H, et al. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness? Aliment Pharmacol Ther. 2004;20:451–8. doi: 10.1111/j.1365-2036.2004.02096.x. [DOI] [PubMed] [Google Scholar]
101. Wong BCY, Wong WM, Yee YK, et al. Rabeprazole-based 3-day and 7-day triple therapy vs omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2001;15:1959–65. doi: 10.1046/j.1365-2036.2001.01118.x. [DOI] [PubMed] [Google Scholar]
102. Yang K, Wang G, Chen J, et al. Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer. J Formos Med Assoc. 2003;102:857–62. [PubMed] [Google Scholar]